TY - JOUR
T1 - New approaches for the detection of minimal residual disease in acute myeloid leukemia
AU - Van Rhenen, Anna
AU - Moshaver, Bijan
AU - Ossenkoppele, Gert J.
AU - Schuurhuis, Gerrit Jan
N1 - Funding Information:
25. Kern W, Schoch C, Haferlach T, Schnittger S: Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol 2005, 56:283–309. Baer MR, Stewart CC, Dodge RK, et al.: High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001, 97:3574–3580. Kern W, Danhauser-Riedl S, Ratei R, et al.: Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003, 88:646–653. Roederer M, De Rosa S, Gerstein R, et al.: 8 color, 10-parameter flow cytometry to elucidate complex leukocyte heterogeneity. Cytometry 1997, 29:328–339. Voskova D, Schnittger S, Schoch C, et al.: Use of five-color staining improves the sensitivity of multiparameter flow cyto-meric assessment of minimal residual disease in patients with acute myeloid leukemia. Leuk Lymphoma 2007, In press. Schnittger S, Weisser M, Schoch C, et al.: New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantifi-cation of fusion transcripts. Blood 2003, 102:2746–2755. Guerrasio A, Pilatrino C, De Micheli D, et al.: Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002, 16:1176–1181. Gallagher RE, Yeap BY, Bi W, et al.: Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute pro-myelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003, 101:2521–2528. Grimwade D, Walker H, Oliver F, et al.: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998, 92:2322–2333. van Dongen JJ, Macintyre EA, Gabert JA, et al.: Standard-ized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999, 13:1901–1928. Schnittger S, Schoch C, Dugas M, et al.: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leuke-mia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detec-tion of minimal residual disease. Blood 2002, 100:59–66. Cloos J, Goemans BF, Hess CJ, et al.: Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006, 20:1217–1220. Burmeister T, Marschalek R, Schneider B, et al.: Monitoring minimal residual disease by quantification of genomic chro-mosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia 2006, 20:451–457.
PY - 2007/4
Y1 - 2007/4
N2 - The detection of minimal residual disease (MRD) in patients with acute leukemia has been studied for about 15 years by different groups in both the United States and Europe. It has been found that MRD detection can be performed using molecular and immunophenotypic aberrancies that are present in the leukemic clone at diagnosis and not in normal bone marrow. When performing MRD assessments after chemotherapy, it is possible to identify patients at risk for relapse. This review is not an overview of all MRD studies, but rather discusses the possibilities for optimizing MRD detection, the use of flow cytometry versus polymerase chain reaction techniques, and the implications for future patient treatment. When informative, we compare literature on MRD in acute myeloid leukemia (AML) with information from MRD studies in acute lymphoblastic leukemia. Finally, we address the promising detection of AML stem cells, the likely cells of origin in AML, for prediction of clinical outcome and guidance of future therapies.
AB - The detection of minimal residual disease (MRD) in patients with acute leukemia has been studied for about 15 years by different groups in both the United States and Europe. It has been found that MRD detection can be performed using molecular and immunophenotypic aberrancies that are present in the leukemic clone at diagnosis and not in normal bone marrow. When performing MRD assessments after chemotherapy, it is possible to identify patients at risk for relapse. This review is not an overview of all MRD studies, but rather discusses the possibilities for optimizing MRD detection, the use of flow cytometry versus polymerase chain reaction techniques, and the implications for future patient treatment. When informative, we compare literature on MRD in acute myeloid leukemia (AML) with information from MRD studies in acute lymphoblastic leukemia. Finally, we address the promising detection of AML stem cells, the likely cells of origin in AML, for prediction of clinical outcome and guidance of future therapies.
UR - http://www.scopus.com/inward/record.url?scp=34248361570&partnerID=8YFLogxK
U2 - 10.1007/s11899-007-0016-0
DO - 10.1007/s11899-007-0016-0
M3 - Review article
C2 - 20425359
AN - SCOPUS:34248361570
SN - 1558-8211
VL - 2
SP - 111
EP - 118
JO - Current Hematologic Malignancy Reports
JF - Current Hematologic Malignancy Reports
IS - 2
ER -